JBIO SCHEDULE 13G/A: SEC filing
Paradigm BioCapital Advisors LP and affiliated reporting persons
Filed with the SEC on · accession 0001104659-26-128317
JBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Paradigm BioCapital Advisors LP and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 6,053,268 shares, or 9.5%, of Jade Biosciences common stock as of September 30, 2026. The stock moved -5.1% by the first close after the filing.
Summary of the filing
Paradigm BioCapital Advisors LP and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 6,053,268 shares, or 9.5%, of Jade Biosciences common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(c).
Key details
How JBIO stock reacted
Close before
$16.14
Nov 13, 2026
First close after
-5.08%
$15.32
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for JBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for JBIO?
Click hereFrequently asked questions
What did JBIO file with the SEC on Nov 16, 2026?
JBIO filed a SCHEDULE 13G/A (SEC filing). Paradigm BioCapital Advisors LP and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 6,053,268 shares, or 9.5%, of Jade Biosciences common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(c).
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did JBIO stock react to this filing?
JBIO closed at $16.14 before the filing and $15.32 on Nov 16, 2026 (-5.08%).
Other JBIO SEC filings
- 8-K · SEC filingNov 13, 2026
- 10-Q · SEC filingNov 13, 2026
- SCHEDULE 13G · SEC filingOct 28, 2026
- SCHEDULE 13G · SEC filingOct 27, 2026
- 8-K · SEC filingSep 30, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- 10-Q · SEC filingAug 10, 2026
- 8-K · SEC filingAug 10, 2026
- 8-K · Material agreementJul 1, 2026
Get alerts when JBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days